Dow makes $1.5bn divestiture plans


US chemical giant Dow has announced plans to sell more parts of its ‘non-core’ business, adding that it will target ‘an increased divestiture list of nearly $1.5 billion (£1 billion) over the next 18 months’.

The company had identified two parts in particular: the ‘polypropylene licensing and catalysts’ business unit and the plastics additives unit.

‘We are reviewing our entire portfolio and seeking even further opportunities to optimise value: selectively pruning assets that are no longer a strategic or financial fit,’ said Dow chair and chief executive Andrew Liveris.

In October 2012, Dow announced plans to cut 2400 jobs, representing 5% of its global workforce, and close 20 manufacturing plants, in a bid to shave $500 million off its annual costs over the next two years. Since then, it has struck deals to sell the stabilisers component of its plastics additives business and its 50% stake ownership in Nippon Unicar Company – a Japanese joint venture with Tonen Chemical.


Related Content

Copper catalysis sees the light

28 March 2013 Research

news image

Copper nanoparticle's oxidation state can be tuned using visible light, enabling industrially important propylene epoxidation

Going for silver: green plastic production

9 April 2010 News Archive

news image

A new class of silver based catalysts for propylene oxide formation based on subnanometer clusters of three silver atoms

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company